Abercrombie & Fitch Co. director Helen Vaid converted 2,089 Restricted Stock Units (RSUs) into an equal number of Class A Common Stock shares on June 3, 2026. This transaction was a compensation-related equity transfer rather than an open-market trade, increasing her direct holdings to 7,161 shares of Class A Common Stock. The RSUs vest based on either the first anniversary of the grant date or the next annual meeting of stockholders.

Abercrombie & Fitch Co. director Arturo Nunez has increased his equity stake by exercising restricted stock units for 2,089 shares of Class A Common Stock, bringing his direct common stock holdings to 2,869 shares. Additionally, he received a new grant of 2,160 restricted stock units, raising his direct RSU holdings to 4,249 units. These RSUs will vest on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders.

Abercrombie & Fitch director Helen McCluskey increased her equity stake through compensation-related stock activity. She exercised 2,089 restricted stock units into Class A Common Stock and received a new grant of 2,160 restricted stock units, bringing her total direct holdings to 36,839 shares and 4,249 RSUs. The RSUs will vest on the earlier of the first anniversary of the grant date or the next annual stockholders' meeting, with no open-market purchases or sales reported.

Devon Energy Corporation has filed a prospectus supplement to register up to 175,000 shares of its common stock, which are issuable upon the conversion of Coterra Energy Operating Co.'s 8 1/8% Series A Cumulative Perpetual Convertible Preferred Stock. This registration is associated with the merger of a Devon subsidiary into Coterra Energy Inc. A legal opinion regarding the validity of these shares from Skadden, Arps, Slate, Meagher & Flom LLP has been included as Exhibit 5.1 in the 8-K filing.

American Vanguard Corp (AVD) director Mark R. Bassett was granted 31,872 deferred stock units (DSUs) as part of the company's 2026 non-management director compensation program. Following this award, Bassett directly holds a total of 89,919 shares or DSUs. These DSUs convert into common shares upon cessation of his board service, a change of control, or his death, and do not carry voting or dividend rights before settlement.

Anuj Gaggar, Chief Medical Officer at Assembly Biosciences (ASMB), received an equity grant of 14,000 restricted stock units (RSUs) at $0.00 per share. This grant was contingent upon stockholder approval of an amendment to the company's 2018 Stock Incentive Plan, which occurred on June 4, 2026. The RSUs will vest in four equal annual installments starting March 29, 2027, provided continuous service, and Gaggar now holds a total of 42,688 common shares.

Assembly Biosciences' Chief Manufacturing Officer, Nicole S. White, was granted 14,000 restricted stock units (RSUs) as part of her annual equity compensation. This grant, approved on March 29, 2026, became issuable after stockholders approved an amendment to the company’s 2018 Stock Incentive Plan on June 4, 2026. The RSUs will vest in four equal installments from 2027 to 2030, and following this, White now directly holds 48,145 shares of common stock.

HeartBeam, Inc. is seeking shareholder approval to amend its 2022 Equity Incentive Plan to increase the authorized shares by 3,000,000, raising the total cap to 14,900,000 shares. This proposal aims to support ongoing equity grants for executives, employees, and directors, aligning their interests with shareholders and attracting key talent. Shareholders will also vote on the election of nine directors and the ratification of CBIZ CPAs P.C. as the independent auditor at the virtual 2026 Annual Meeting on July 31, 2026.

Abbott Laboratories has petitioned the U.S. Tax Court, asserting that it should not be required to recognize an $8 billion gain from 2020. The company argues this gain, which resulted from transactions among its controlled foreign corporations, should go untaxed due to a timing mismatch.

Acumen Pharmaceuticals director Dr. Laura Stoppel was granted 35,500 restricted stock units and stock options for 53,250 shares with a $2.29 exercise price. These equity awards are held for the benefit of RA Capital Healthcare Fund, RA Capital Nexus Fund II, and a separately managed account, with any net stock or cash offsetting advisory fees owed to RA Capital Management. The reporting persons (RA Capital entities and associated individuals) disclaim beneficial ownership beyond their pecuniary interest.